Growth in the medtech and pharmaceutical sector in Victoria has earnt $2.2 billion in exports in 2018. Pharmaceuticals are now the highest-value manufactured export product in the state and grew by 255 per cent over the past four years. “Victoria’s medtech and pharma industry is one of this state’s most important sectors, not only for … Continue reading Medtech manufacturing leads Victorian export boom
A new, automated medical pathology laboratory has been scaled down to the size of a chip, to enable doctors to find alternatives to anti-blood clotting medications. The tiny device is a biocompatible lab-on-a-chip, will enable the development of methods to prevent the formation of blood clots and reducing the risk of excessive, life-threatening bleeding. “We’ve … Continue reading Micro-system for pharmaceutical testing
The University of Technology Sydney (UTS) has opened a new biotech production and training facility. The Biologicals Innovation Facility (BIF) is the result of a partnership between UTS, the NSW government and GE Healthcare. The facility includes clean rooms and containment laboratories which will house research into and the development of biopharmaceuticals. Courses for students … Continue reading University, government, and industry partner for new biotech facility
The Australian Trade and Investment Commission (Austrade) is seeking to showcase the potential of medical manufacturing in Australia to inspire international investment. Launching a new digital health website, Austrade highlights Australia’s attractiveness as a location for developing, testing and launching new medical technologies. Denise Eaton, senior advisor at Austrade noted that Australia is inherently primed … Continue reading Federal government agency steps up support for medical manufacturing
Australian medicine manufacturers, Vitex Pharmaceuticals, has signed an agreement with the NSW Government to build a pharmaceutical training and research facility at the Western Sydney Aerotropolis. NSW Premier Gladys Berejiklian said the agreement with Vitex paves the way for the company to invest an initial $10 million in a 10,000 square metre facility to support … Continue reading Vitex to build pharmaceutical training facility in Western Sydney Aerotropolis
This time each year IBISWorld delivers Manufacturers’ Monthly a list of the top 100 manufacturers in Australia. Alan Johnson investigates how the various sectors ranked on this year’s list.
The US Food and Drug Administration has approved the first 3D printed drug product, Aprecia’s Spritam.
Workers at Dandenong South’s Aspen Pharmaceuticals continued to strike over the weekend over revised pay and conditions affecting over half the factory’s workforce.
The pharmaceutical industry will require government support if it is to compete globally, according to a key industry figure.
Pharmaceutical company Pfizer plans to shut down its manufacturing plant in the Sydney suburb of West Ryde in 2015.
Jonathan Wilkins of European Automation examines the implications of the latest update CFR21/11 to 21 CFR part 11 of Code of Federal Regulations of FDA.
Brent Balinski spoke to Professor Peter Gahan from the University of Melbourne and Jeffery Yeh from Homart Pharmaceuticals about the importance of High Performance Work Practices to small and medium enterprise companies.
Samsung had earlier claimed they manufacture biosimilars at half the cost of what Western drugmakers would have to charge.
SciGen Ltd has concluded a memorandum of understanding to sell its SciGen BioPharma joint venture to Anglo Gulf.
German Pharmaceutical company Fresenius Kabi Australia will build a $47 million manufacturing plant at Derrimut in Melbourne’s west.
Since the industrial revolution manufacturing has meant cumbersome factories, production lines, machinery, labour and striving for the creation of economies of scale.
While conditions in the Australian manufacturing industry remain challenging amid weakness in the global economy, there are certain companies that are bucking the trend and taking advantage of strong opportunities for growth.
Pharmaceutical giant CSL will farewell its CEO Brian McNamee who has been one of Australia’s longest-serving chief executives.
A combination of ongoing industrial relations issues and a strong Aussie dollar have prompted healthcare manufacturer CSL to consider moving manufacturing operations offshore.
Australia’s car industry is faltering and our wine sector is facing increasing offshore competition, however, there is good news when it comes to pharmaceutical manufacturers, Alex Heber reports.